Organigram Finalizes $10 Million Strategic Investment to Develop Cannabinoids from Yeast

Visit the OrganiGram Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.

Organigram invests in Hyasynth Biologicals Inc., helps bring transformative “cellular agriculture” to Canadian cannabis industry

Investment solidifies Organigram’s commitment to next generation delivery of cannabinoid products to global medical and adult recreational cannabis markets

MONCTON, NB, Sept. 13, 2018 /CNW/ – Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQX: OGRMF), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of medical marijuana, is pleased to announce the closing of its strategic investment in convertible secured debentures (the “Debentures”), to be purchased in three tranches and valued in the aggregate at $10 million, of Hyasynth Biologicals Inc. (“Hyasynth”), a biotechnology company based in Montreal and leader in the

... read more at: https://www.newcannabisventures.com/organigram-finalizes-10-million-strategic-investment-to-develop-cannabinoids-from-yeast/

by

Leave a Reply